.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,612,208

« Back to Dashboard
Patent 7,612,208 protects LENVIMA and is included in one NDA.

This patent has thirty-four patent family members in twenty-three countries.

Summary for Patent: 7,612,208

Title:Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide or the solvate of the salt and a process for preparing the same
Abstract: A crystal of a 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinoli- necarboxamide hydrochloride, hydrobromide, p-toluenesulfonate, sulfate, methanesulfonate or ethanesulfonate, or a solvate thereof.
Inventor(s): Matsushima; Tomohiro (Tsukuba, JP), Nakamura; Taiju (Kamisu, JP), Yoshizawa; Kazuhiro (Kamisu, JP), Kamada; Atsushi (Tsukuba, JP), Ayata; Yusuke (Kamisu, JP), Suzuki; Naoko (Ushiku, JP), Arimoto; Itaru (Tokyo, JP), Sakaguchi; Takahisa (Tsukuba, JP), Gotoda; Masaharu (Tsukuba, JP)
Assignee: Eisai R&D Management Co., Ltd. (Tokyo, JP)
Application Number:10/577,531
Patent Claim Types:
see list of patent claims
Compound; Process; Composition; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Organic fine chemistry
Back Citations: 13th percentile
Forward Citations: 6th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-001Feb 13, 2015RXNo7,612,208► subscribeYY
Eisai Inc
LENVIMA
lenvatinib mesylate
CAPSULE;ORAL206947-002Feb 13, 2015RXYes7,612,208► subscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,612,208

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2003-430939Dec 25, 2003
PCT Information
PCT FiledDecember 22, 2004PCT Application Number:PCT/JP2004/019223
PCT Publication Date:July 14, 2005PCT Publication Number: WO2005/063713

International Patent Family for Patent: 7,612,208

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2004309217► subscribe
BrazilPI0418200► subscribe
Canada2543650► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc